The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

A first-in-human, phase 1a/b, dose-escalation/expansion study of BG-68501, a selective CDK2 inhibitor, as monotherapy or in combination with fulvestrant for patients with HR+/HER2- breast cancer and other advanced solid tumors: First disclosure of clinical data.

Rohit  Joshi

Honoraria - Bristol-Myers Squibb; Gilead Sciences; Ipsen; Merck Sharp & Dohme; Pfizer; Pfizer/EMD Serono; Roche

Consulting or Advisory Role - AstraZeneca; Merck Sharp & Dohme; Roche

Speakers' Bureau - Gilead Sciences

Travel, Accommodations, Expenses - Novartis

Dimitros  Zardavas

Employment - BeOne Medicines Ltd

Alejandra  Ragone

Employment - BeOne Medicines Ltd

Sandra  Chica-Duque

Employment - BeOne Medicines Ltd

Yang  Wang

Employment - BeOne Medicines Ltd

Yixi  Liu

Employment - BeOne Medicines Ltd

Yang  Liu

Employment - BeOne Medicines Ltd

Ying  Cao

Employment - BeOne Medicines Ltd

Brian  Van Tine

Leadership - Polaris

Honoraria - Beijing Biostar Pharmaceuticals Co., Ltd.; Oncology Education; Total Health Conference

Consulting or Advisory Role - Aadi; Acuta Capital Partners, LLC; Adaptimmune; Advenchen Laboratories; Boxer Capital LLC; Crisper Therapeutics; Daiihi Sankyo; Deciphera; Galapagos NV; Hinge Bio; Kronos Bio, Inc.; Putnam Associates; Salarius Pharmaceuticals, INc.; Syneos Health

Research Funding - Polaris

Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker

Expert Testimony - Health Advances

Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Kronos Bio, Inc